Safety Concerns Arise for Low-level red light (LLRL) therapy Myopia Treatment Devices
In the quest to combat myopia, a common eye condition affecting millions worldwide, innovative therapies have emerged. One such treatment, Low-level red light (LLRL) therapy, has garnered attention for its potential to reduce myopia progression in children. However, recent research has shed light on a concerning aspect of these treatments: safety limits may be exceeded, posing risks to the eyes of young patients.
A study led by Lisa A Ostrin and Alexander W Schill delved into the output and safety parameters of two LLRL devices commonly used for myopia control. Their findings, published in a recent issue of Optometry and Vision Science, unveil alarming insights into the potential hazards associated with these treatments.
The devices under scrutiny, the Sky-n1201a and the Future Vision, were subjected to rigorous examination. Optical power measurements were conducted following ANSI Z136.1-2014 guidelines, revealing critical data regarding corneal and retinal irradiance. What emerged from this analysis is a troubling revelation: prolonged exposure to these devices, even within recommended usage guidelines, could exceed safety thresholds, placing the delicate tissues of the eye at risk.
The Sky-n1201a, emitting a 654-nanometer wavelength, was found to deliver laser light concentrated as a point source. While seemingly innocuous with its 0.2 milliwatts of power output, closer inspection reveals corneal and retinal irradiance levels that could induce thermal and photochemical damage with just minutes of continuous exposure. Similarly, the Future Vision device, though emitting a lower power output of 0.06 milliwatts, still posed significant risks due to its extended source configuration.
The implications of these findings are profound, particularly in the context of pediatric myopia treatment. With children’s eyes being more susceptible to damage from intense light exposure, the potential for harm is heightened. Indeed, the study’s authors caution against the indiscriminate use of LLRL therapy for myopia until stringent safety standards can be established and confirmed.
This raises critical questions for clinicians and caregivers alike. How can the benefits of myopia treatment be weighed against the inherent risks of LLRL therapy? Are current safety standards adequate to protect vulnerable young patients? These concerns underscore the need for further research and regulatory oversight in the field of myopia management.
As we navigate the complexities of ocular health and innovation, it is imperative that safety remains paramount. While LLRL therapy holds promise as a potential solution for myopia, its implementation must be approached with caution. Until comprehensive safety guidelines are established, the eyes of our children hang in the balance, awaiting assurances that their vision is not compromised in the pursuit of treatment.
Reference-ncbi
Follow us in Facebook for Optometry diagnosis challenge
